MVA-5T4 immunotherapy (TroVax) and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): an open-label, randomized phase 1/2 clinical trial
2017
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI